Researchers Highlight Advances in Cryopreserved Amniotic Membrane for Challenging Eye Conditions at ASCRS 2026

Studies Presented Include Research Evaluating BioTissue Products Across a Range of Complex Ocular Surface Conditions

MIAMI, April 7, 2026—New clinical findings presented at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., examine the use of cryopreserved amniotic membrane (CAM) in the treatment of complex and difficult-to-treat ocular surface conditions, including studies evaluating BioTissue products. Across multiple paper and poster presentations, researchers reported improved outcomes after treatment with CAM in cases where standard therapies had limited effect.

In a key paper presentation, CAM360 with Collagen Shield vs. Bandage Contact Lens in Recalcitrant Keratopathy, Taylor Linaburg, MD, evaluated whether cryopreserved amniotic membrane (BioTissue CAM360 AmnioGraft^™) with collagen shield accelerates recovery compared with conventional bandage contact lenses. Early findings indicated that the graft plus collagen shield promoted healing and improved outcomes, highlighting the potential of tissue-restoring approaches for recalcitrant ocular surface disease.

A second paper, Amniograft for Eyelid and Periorbital Burns, by Lauren Nakhleh, MD, examined the use of cryopreserved amniotic membrane (BioTissue AmnioGraft^™) for patients with eyelid and periocular burns. The grafts supported complete epithelialization, limited scarring, and preserved eyelid structure, suggesting a promising strategy for functional recovery and long-term outcomes in burn-affected tissue.

In addition to the podium sessions, seven scientific posters explored BioTissue’s CAM360 AG and Prokera^® Slim products for a variety of eye surface indications, including autoimmune-related neurotrophic keratitis, ocular surface disease, anterior corneal disorders, corneal ulcers, and cases requiring superficial keratectomy. Collectively, these reports reinforced trends toward complete healing, symptom reduction, and improved visual function, underscoring the versatility of biologic therapies in challenging clinical scenarios.

“We’re proud to see BioTissue’s advanced technology consistently featured alongside leading ocular surface research at ASCRS,” said Ted Davis, President and CEO of BioTissue. “This year’s studies reflect a broader shift toward regenerative interventions, particularly for patients who haven’t found success with conventional treatments. With a deeper understanding of ocular surface biology, the focus is shifting to therapies that promote active healing and long-term outcomes, rather than simply managing patients’ symptoms.”

The research will be presented throughout the ASCRS annual meeting, with posters available for on-demand viewing in the Education Hub during the conference and online following the meeting.

# # #

About BioTissue Holdings, Inc. 

BioTissue® is an emerging biotechnology company and leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, specializing in acute and chronic ocular surface conditions. BioTissue’s portfolio of cryopreserved amniotic membrane products are processed using its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with Investigational New Drug (IND) applications as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 1.2 million human procedures with its products and published over 440 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at www.biotissue.com/.

Media Contact

Laura DiCaprio

McDougall Communications for BioTissue

[email protected] or (585) 434-2153